{"brief_title": "Phase 2 Evaluation of the ELAD System in the Management of Acute Liver Failure", "brief_summary": "The purpose of this study is to determine if treatment with the ELAD Bioartificial Liver Assist Device is beneficial to patients in Acute Liver Failure either as a bridge to liver transplant or bridge to native liver recovery.", "detailed_description": "Current treatment with modalities in Acute Liver Failure still carry unacceptable morbidity and mortality. It is hoped that by intervening with ELAD a patient will have an opportunity to be bridged to transplant or to avoid transplantation and to have their native liver recover.", "condition": "Fulminant Hepatic Failure", "intervention_type": "Other", "intervention_name": "Standard of care (Control)", "arm_group_label": "Standard of care (Control)", "other_name": "Extracorporeal Liver Assist Device", "criteria": "Inclusion criteria: - Clinical diagnosis of Fulminant Hepatic Failure with encephalopathy, and coagulopathy - Weight not less than 40 kilograms - Not listed for organ transplant, but no medical contraindications for transplant Exclusion Criteria: - Listed for organ transplant at stud entry - History of jaundice for greater than 28 days at screening - Liver dysfunction due to trauma - Concomitant serious disease", "gender": "All", "minimum_age": "18 Years", "maximum_age": "50 Years", "healthy_volunteers": "No", "id": "NCT00030225.xml"}